Figure 12.
Major bleeding in venous thromboembolic event patients by renal function. Major bleeding data for dabigatran, apixaban and rivaroxaban according to renal function subgroups as reported by Geldhof et al. 40 Data are reported as risk ratios of nonvitamin K antagonist oral anticoagulant versus warfarin. The definition of major bleeding was similar in all included trials and conformed to the International Society on Thrombosis and Haemostasis guidelines. Major bleeding data for edoxaban by renal function was not available at the time of publication.
Comp, comparator arm; CNOAC, nonvitamin K antagonist oral anticoagulant; CrCl, creatinine clearance; DVT, deep vein thrombosis; PE, pulmonary embolism.